Veranex announced that it has acquired T3 Labs for an undisclosed price. T3 Labs is a contract research organization (CRO) in Atlanta offering preclinical testing services. The company brings devices, drugs and biologics from concept to commercialization.
Founded in 2021, Veranex is a comprehensive, global, tech-enabled service provider dedicated to the MedTech industry. Offering expert guidance from concept to commercialization and across the development continuum, Veranex enables accelerated speed to market, controlled development costs, development risk mitigation and accelerated market viability assessment. Veranex is backed by Summit Partners, Accelmed and Lauxera Capital Partners.
This acquisition solidifies Veranex’s commitment to expanding its preclinical footprint in North America, deepening its therapeutic expertise and providing clients with enhanced flexibility. According to data captured in the LevinPro HC database, this acquisition is the 42nd CRO transaction of the year. This is a slight increase over last year when there were 40 CRO transactions announced between January 1, 2022, and December 15, 2022.
